News

Tuesday February 8, 2022

Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme Phase 3 can use similar primary endpoint to the […]

Tuesday February 1, 2022

Positive data in XF-73 Dermal study with NIAID

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive results in XF-73 Dermal safety study from ongoing agreement with US Government’s NIAID Brighton, United Kingdom, 1 February 2022 – Destiny […]